United States

AFFO (TTM)

AFFO/share (TTM)

AFFO/share Guidance

AFFO (Quarter)

AFFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/AFFO

Size (ft²)

Occupancy

The Company is a fully integrated REIT primarily focused on the ownership, acquisition, development and management of
retail properties net leased to industry leading tenants.

Agree Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, ADC is classified as investment grade

Period: 2023 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's Adjusted FFO

Adjusted FFO Growth

Assessment of recent increases in Adjusted FFO per share, indicating profitability

Adjusted FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Envestnet Asset Management Inc. boosted its position in Agree Realty Corporation (NYSE: ADC) by 12.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 319,211 shares of the real estate investment trust's stock after purchasing an additional 36,312

Envestnet Asset Management Inc. Increases Stake in Agree Realty Corporation $ADC

Real estate investment trusts (REITs) tend to shine when there is a lid on interest rates. And that rate top is secure, for reasons we'll review shortly.

2 Triple Net Lease REITs Set To Gain As Interest Rates Tick Lower

Passive income is revenue generated without the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.

Retirees Rely On These 5 Safe High-Yield Monthly Pay Dividend Stocks

CEO Abizer Gaslightwala discusses the Company's recent announcement around its ADC pipeline expansion and IP strategy

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter and full year ended December 31, 2025. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. Fourth Quarter 2025 Financial and Operating Highlights: Invested approximately $377 million in 94 retail net lease properties across all three external growth platforms Commenced four development or Developer Funding Platform (“D.

Agree Realty Corporation Reports Fourth Quarter and Full Year 2025 Results

Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board ("SAB") meeting held on January 30, 2026, focused on advancing the strategic positioning of Accum® for antibody-drug conjugate ("ADC") applications. The discussion brought together complementary expertise spanning ADC chemistry and development, experimental design and translational science, and value creation and partnering strategy, enabling an in-depth and highly constructive exchange on Accum®'s role in improving intracellular delivery of ADC payloads.

Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board

I spent most of last month pulling apart net lease credit structures — Realty Income's A- rating, NNN REIT's longer-dated debt stack, the mechanics of how buffer distance from the BBB- cliff translates into real-world resilience. Each time, the question was the same: how much room does this company have before something breaks?

Why Agree Realty Guided Lower for 2026, Despite a Strong Balance Sheet

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.262 per common share. The monthly dividend reflects an annualized dividend amount of $3.144 per common share, representing a 3.6% increase over the annualized dividend amount of $3.036 per common share from the first quarter of 2025. The dividend is payable March 13, 2026 to stockholders of.

Agree Realty Declares Monthly Common and Preferred Dividends

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. DS3790 is a specifically engineered, potential first-in-class CD37 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568). CD37 is a transmembrane protein that plays a role in regulating cell survival and is overexpressed on malignant B-cells, making it a promising th.

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

LAUSANNE, Switzerland, Feb. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 308,000 of the Company's common shares to seven new employees on February 2, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct to address one of oncology's most challenging and valuable solid tumor targets, CEACAM5 TAMPA and LONDON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-splicing payloads, today announced the filing of a new U.S. provisional patent application (No. 63/958,508) covering its second pipeline candidate, AKTX-102, an ADC directed against CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated but historically difficult-to-drug oncology target.

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Strs Ohio raised its stake in shares of Agree Realty Corporation (NYSE: ADC) by 79.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 194,492 shares of the real estate investment trust's stock after purchasing an additional 85,935 shares during the

Agree Realty Corporation $ADC Shares Bought by Strs Ohio

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.262 per common share. The monthly dividend reflects an annualized dividend amount of $3.144 per common share, representing a 3.6% increase over the annualized dividend amount of $3.036 per common share from the first quarter of 2025. The dividend is payable February 13, 2026 to stockholders.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with risvutatug rezetecan (also known as GSK'227), GSK's novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC). “We believe exploring new mec.

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equivalents of approximately $261M as of December 31, 2025, provide expected cash runway at least to 2028 Anticipated near-term catalysts include LOTIS-7 complete enrollment in first half of 2026 and LOTIS-5 Phase 3 topline data in second quarter 2026 Additional anticipated catalysts include full LOTIS-5 and LOTIS-7 results by end of 2026, with potential compendia inclusions in first half of 2027 and LOTIS-5 regulatory approvals to follow LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today provided corporate updates and highlights from its ZYNLONTA® clinical program. "During 2025, we delivered meaningful progress across our ZYNLONTA clinical program and extended our expected cash runway at least to 2028," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.

ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 15, 2026, at 10:30 a.m.

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

CoreCap Advisors LLC boosted its holdings in shares of Agree Realty Corporation (NYSE: ADC) by 15.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,044 shares of the real estate investment trust's stock after buying an additional 7,186

CoreCap Advisors LLC Purchases 7,186 Shares of Agree Realty Corporation $ADC

Realty Income is a lumbering giant, but its 5.6% yield could be a cornerstone investment. Agree Realty competes with Realty Income, but it is much smaller, so its 4.3% yield comes with a growth kicker.

3 Stocks That Cut You a Check Each Month

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its fourth quarter and full year 2025 operating results after the market closes on Tuesday, February 10, 2026. A conference call to discuss the Company's operating results is scheduled for Wednesday, February 11, 2026, at 9:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (800) 715-9871   Intern.

Agree Realty Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Information

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced a summary of its investment activity in 2025, introduced investment guidance for 2026, and provided an update on its portfolio as well as its fourth quarter capital markets activity. 2025 Investment Activity Total real estate investment volume for 2025, inclusive of acquisition, development, and Developer Funding Platform (“DFP”) projects completed or under construction, amounted to a total o.

Agree Realty Announces 2025 Investment Activity & 2026 Investment Outlook

CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-concept data anticipated in first quarter of 2027 Crescent partner Kelun-Biotech receives IND approval for CR-003 (SKB105) by NMPA of China Four clinical trials across portfolio expected to initiate in 2026 WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced regulatory clearances of Investigational New Drug (IND) applications for CR-001, a PD-1 x VEGF bispecific antibody, and CR-003, an integrin beta-6 (ITGB6)-targeted antibody drug-conjugate (ADC), both being developed for the treatment of advanced solid tumors.

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

LAUSANNE, Switzerland, Jan. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 6,000 of the Company's common shares to a new employee on January 2, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.

ADC Therapeutics Announces New Employee Inducement Grant

NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Agree Realty Corporation (NYSE: ADC - Get Free Report) Director John Rakolta, Jr. acquired 15,000 shares of Agree Realty stock in a transaction on Wednesday, December 24th. The stock was purchased at an average price of $72.18 per share, with a total value of $1,082,700.00. Following the transaction, the director directly owned 562,606 shares in the

Agree Realty (NYSE:ADC) Director John Rakolta, Jr. Purchases 15,000 Shares of Stock

ExxonMobil has increased its dividend payment for 43 years in a row. Agree Realty has grown its dividend at a 5.3% compound annual rate over the last 10 years.

The Smartest Dividend Stocks to Buy With $1,000 Right Now

While reaching retirement age can be both a blessing and a curse, relying on the U.S.

Boomers Are Buying These 5 High-Quality Monthly Dividend Stocks Hand Over Fist

Exchange Traded Concepts LLC boosted its stake in Agree Realty Corporation (NYSE: ADC) by 33.2% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,169 shares of the real estate investment trust's stock after acquiring an additional 21,240 shares

Agree Realty Corporation $ADC Shares Acquired by Exchange Traded Concepts LLC

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the "Company") today announced the release of its 2024 Sustainability Report. The report highlights the Company's environmental, social and governance ("ESG") initiatives and is aligned with the ISSB IFRS S1 and S2 disclosure standards. "I'm very pleased to release our fifth annual Sustainability Report," said Joey Agree, President and Chief Executive Officer. "We continue to make considerable progress on our ESG initiativ.

Agree Realty Publishes Fifth Annual Sustainability Report

CEO ABIZER GASLIGHTWALA DISCUSSES THE COMPANY'S RECENT ANNOUNCEMENT AROUND ITS ADC PIPELINE EXPANSION AND IP STRATEGY

AKARI THERAPEUTICS PARTICIPATES IN VIRTUAL INVESTOR WHAT THIS MEANS INTERVIEW DISCUSSING THE COMPANY'S EXPANDED ADC PIPELINE

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED RESULTS FOR THE QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025. ALL PER SHARE AMOUNTS INCLUDED HEREIN ARE ON A DILUTED PER COMMON SHARE BASIS UNLESS OTHERWISE STATED. FOURTH QUARTER 2025 FINANCIAL AND OPERATING HIGHLIGHTS: INVESTED APPROXIMATELY $377 MILLION IN 94 RETAIL NET LEASE PROPERTIES ACROSS ALL THREE EXTERNAL GROWTH PLATFORMS COMMENCED FOUR DEVELOPMENT OR DEVELOPER FUNDING PLATFORM (D.

AGREE REALTY CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS

MONTREAL, QUEBEC--(NEWSFILE CORP. - FEBRUARY 10, 2026) - DEFENCE THERAPEUTICS INC.(CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("DEFENCE" OR THE "COMPANY"), A PUBLICLY TRADED BIOTECHNOLOGY AND PRECISION INTRACELLULAR DRUG-DELIVERY COMPANY, REPORTED ON ITS SCIENTIFIC ADVISORY BOARD ("SAB") MEETING HELD ON JANUARY 30, 2026, FOCUSED ON ADVANCING THE STRATEGIC POSITIONING OF ACCUM FOR ANTIBODY-DRUG CONJUGATE ("ADC") APPLICATIONS. THE DISCUSSION BROUGHT TOGETHER COMPLEMENTARY EXPERTISE SPANNING ADC CHEMISTRY AND DEVELOPMENT, EXPERIMENTAL DESIGN AND TRANSLATIONAL SCIENCE, AND VALUE CREATION AND PARTNERING STRATEGY, ENABLING AN IN-DEPTH AND HIGHLY CONSTRUCTIVE EXCHANGE ON ACCUM'S ROLE IN IMPROVING INTRACELLULAR DELIVERY OF ADC PAYLOADS.

DEFENCE THERAPEUTICS ALIGNS ACCUM ADC STRATEGY THROUGH MULTIDISCIPLINARY SCIENTIFIC ADVISORY BOARD

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.262 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.144 PER COMMON SHARE, REPRESENTING A 3.6% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.036 PER COMMON SHARE FROM THE FIRST QUARTER OF 2025. THE DIVIDEND IS PAYABLE MARCH 13, 2026 TO STOCKHOLDERS OF.

AGREE REALTY DECLARES MONTHLY COMMON AND PREFERRED DIVIDENDS

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--THE FIRST PATIENT HAS BEEN DOSED IN A FIRST-IN-HUMAN PHASE 1/2 TRIAL EVALUATING DS3790 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA. DS3790 IS A SPECIFICALLY ENGINEERED, POTENTIAL FIRST-IN-CLASS CD37 DIRECTED DXD ANTIBODY DRUG CONJUGATE (ADC) DISCOVERED BY DAIICHI SANKYO (TSE: 4568). CD37 IS A TRANSMEMBRANE PROTEIN THAT PLAYS A ROLE IN REGULATING CELL SURVIVAL AND IS OVEREXPRESSED ON MALIGNANT B-CELLS, MAKING IT A PROMISING TH.

DS3790 ENTERS CLINICAL DEVELOPMENT AS FIRST DXD ADC IN HEMATOLOGY FROM INDUSTRY-LEADING ADC PORTFOLIO OF DAIICHI SANKYO

LAUSANNE, SWITZERLAND, FEB. 2, 2026 /PRNEWSWIRE/ --ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE GRANTS OF OPTIONS TO PURCHASE AN AGGREGATE OF 308,000 OF THE COMPANY'S COMMON SHARES TO SEVEN NEW EMPLOYEES ON FEBRUARY 2, 2026 (EACH, A "GRANT"). THE GRANTS WERE OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEES' EMPLOYMENT.

ADC THERAPEUTICS MAKES GRANTS TO NEW EMPLOYEES UNDER INDUCEMENT PLAN

COMPANY EXPANDS ITS ADC PIPELINE AND PATENT ESTATE FOR NOVEL, DIFFERENTIATED ADCS NEW PIPELINE CANDIDATE AKTX-102 LEVERAGES AKARI'S PROPRIETARY PH1 SPLICEOSOME PAYLOAD AND A NOVEL ANTIBODY CONSTRUCT TO ADDRESS ONE OF ONCOLOGY'S MOST CHALLENGING AND VALUABLE SOLID TUMOR TARGETS, CEACAM5 TAMPA AND LONDON, JAN. 26, 2026 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY PIONEERING NEXT-GENERATION ANTIBODY DRUG CONJUGATES (ADCS) POWERED BY NOVEL RNA-SPLICING PAYLOADS, TODAY ANNOUNCED THE FILING OF A NEW U.S. PROVISIONAL PATENT APPLICATION (NO. 63/958,508) COVERING ITS SECOND PIPELINE CANDIDATE, AKTX-102, AN ADC DIRECTED AGAINST CEACAM5 (CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE-5), A WELL-VALIDATED BUT HISTORICALLY DIFFICULT-TO-DRUG ONCOLOGY TARGET.

AKARI THERAPEUTICS FILES KEY PATENT AND UNVEILS SECOND ADC PROGRAM AKTX-102 TARGETING CEACAM5 EXPRESSING SOLID TUMORS

NEW YORK, JAN. 22, 2026 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA ("ADC THERAPEUTICS" OR THE "COMPANY") (NYSE: ADCT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA - ADCT

NEW YORK, JAN. 20, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA (ADC THERAPEUTICS OR THE COMPANY) (NYSE: ADCT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORSOFADC THERAPEUTICS SA - ADCT

NEW YORK, JAN. 15, 2026 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA ("ADC THERAPEUTICS" OR THE "COMPANY") (NYSE: ADCT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JAN. 13, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA (ADC THERAPEUTICS OR THE COMPANY) (NYSE: ADCT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.262 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.144 PER COMMON SHARE, REPRESENTING A 3.6% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.036 PER COMMON SHARE FROM THE FIRST QUARTER OF 2025. THE DIVIDEND IS PAYABLE FEBRUARY 13, 2026 TO STOCKHOLDERS.

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) TODAY ANNOUNCED IT HAS ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH GSK PLC (GSK, LSE/NYSE: GSK) TO EVALUATE IVONESCIMAB, A NOVEL, INVESTIGATIONAL PD-1 / VEGF BISPECIFIC ANTIBODY, IN COMBINATION WITH RISVUTATUG REZETECAN (ALSO KNOWN AS GSK'227), GSK'S NOVEL INVESTIGATIONAL B7-H3 TARGETING ANTIBODY DRUG CONJUGATE (ADC), ACROSS MULTIPLE SOLID TUMOR SETTINGS, INCLUDING SMALL CELL LUNG CANCER (SCLC). WE BELIEVE EXPLORING NEW MEC.

SUMMIT THERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION WITH GSK TO EVALUATE IVONESCIMAB IN COMBINATION WITH GSK'S B7-H3 ANTIBODY DRUG CONJUGATE (ADC)

PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUE OF APPROXIMATELY $22M AND $73M RESPECTIVELY; CASH AND CASH EQUIVALENTS OF APPROXIMATELY $261M AS OF DECEMBER 31, 2025, PROVIDE EXPECTED CASH RUNWAY AT LEAST TO 2028 ANTICIPATED NEAR-TERM CATALYSTS INCLUDE LOTIS-7 COMPLETE ENROLLMENT IN FIRST HALF OF 2026 AND LOTIS-5 PHASE 3 TOPLINE DATA IN SECOND QUARTER 2026 ADDITIONAL ANTICIPATED CATALYSTS INCLUDE FULL LOTIS-5 AND LOTIS-7 RESULTS BY END OF 2026, WITH POTENTIAL COMPENDIA INCLUSIONS IN FIRST HALF OF 2027 AND LOTIS-5 REGULATORY APPROVALS TO FOLLOW LAUSANNE, SWITZERLAND, JAN. 8, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY PROVIDED CORPORATE UPDATES AND HIGHLIGHTS FROM ITS ZYNLONTA CLINICAL PROGRAM. "DURING 2025, WE DELIVERED MEANINGFUL PROGRESS ACROSS OUR ZYNLONTA CLINICAL PROGRAM AND EXTENDED OUR EXPECTED CASH RUNWAY AT LEAST TO 2028," SAID AMEET MALLIK, CHIEF EXECUTIVE OFFICER OF ADC THERAPEUTICS.

ADC THERAPEUTICS PROVIDES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 REVENUE AND CASH ESTIMATES AND RECENT CORPORATE UPDATES

NEW YORK, JAN. 8, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA ("ADC THERAPEUTICS" OR THE "COMPANY") (NYSE: ADCT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

LAUSANNE, SWITZERLAND, JAN. 8, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT AMEET MALLIK, CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE IN SAN FRANCISCO, CA, ON THURSDAY, JANUARY 15, 2026, AT 10:30 A.M.

ADC THERAPEUTICS TO PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT IT WILL RELEASE ITS FOURTH QUARTER AND FULL YEAR 2025 OPERATING RESULTS AFTER THE MARKET CLOSES ON TUESDAY, FEBRUARY 10, 2026. A CONFERENCE CALL TO DISCUSS THE COMPANY'S OPERATING RESULTS IS SCHEDULED FOR WEDNESDAY, FEBRUARY 11, 2026, AT 9:00 AM ET. INTERESTED PARTIES AND SHAREHOLDERS MAY ACCESS THE CALL VIA TELECONFERENCE OR WEBCAST: TELECONFERENCE: USA TOLL FREE (800) 715-9871  INTERN.

AGREE REALTY ANNOUNCES FOURTH QUARTER 2025 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION

NEW YORK, JAN. 06, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA (ADC THERAPEUTICS OR THE COMPANY) (NYSE: ADCT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED A SUMMARY OF ITS INVESTMENT ACTIVITY IN 2025, INTRODUCED INVESTMENT GUIDANCE FOR 2026, AND PROVIDED AN UPDATE ON ITS PORTFOLIO AS WELL AS ITS FOURTH QUARTER CAPITAL MARKETS ACTIVITY. 2025 INVESTMENT ACTIVITY TOTAL REAL ESTATE INVESTMENT VOLUME FOR 2025, INCLUSIVE OF ACQUISITION, DEVELOPMENT, AND DEVELOPER FUNDING PLATFORM (DFP) PROJECTS COMPLETED OR UNDER CONSTRUCTION, AMOUNTED TO A TOTAL O.

AGREE REALTY ANNOUNCES 2025 INVESTMENT ACTIVITY & 2026 INVESTMENT OUTLOOK

CR-001 IND CLEARED BY U.S. FDA; PHASE 1/2 ASCEND GLOBAL CLINICAL TRIAL TO EVALUATE CR-001 IN FIRST-LINE AND PREVIOUSLY TREATED PATIENTS ON TRACK TO INITIATE IN FIRST QUARTER OF 2026, WITH PROOF-OF-CONCEPT DATA ANTICIPATED IN FIRST QUARTER OF 2027 CRESCENT PARTNER KELUN-BIOTECH RECEIVES IND APPROVAL FOR CR-003 (SKB105) BY NMPA OF CHINA FOUR CLINICAL TRIALS ACROSS PORTFOLIO EXPECTED TO INITIATE IN 2026 WALTHAM, MASS., JAN. 05, 2026 (GLOBE NEWSWIRE) -- CRESCENT BIOPHARMA, INC. (CRESCENT OR THE COMPANY) (NASDAQ: CBIO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO RAPIDLY ADVANCING THE NEXT WAVE OF THERAPIES FOR CANCER PATIENTS, TODAY ANNOUNCED REGULATORY CLEARANCES OF INVESTIGATIONAL NEW DRUG (IND) APPLICATIONS FOR CR-001, A PD-1 X VEGF BISPECIFIC ANTIBODY, AND CR-003, AN INTEGRIN BETA-6 (ITGB6)-TARGETED ANTIBODY DRUG-CONJUGATE (ADC), BOTH BEING DEVELOPED FOR THE TREATMENT OF ADVANCED SOLID TUMORS.

CRESCENT BIOPHARMA ANNOUNCES REGULATORY CLEARANCES OF IND APPLICATIONS FOR CR-001, A PD-1 X VEGF BISPECIFIC ANTIBODY AND CR-003, AN ITGB6-TARGETED ADC, FOR THE TREATMENT OF SOLID TUMORS

LAUSANNE, SWITZERLAND, JAN. 2, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE A GRANT OF OPTIONS TO PURCHASE AN AGGREGATE OF 6,000 OF THE COMPANY'S COMMON SHARES TO A NEW EMPLOYEE ON JANUARY 2, 2026 ("GRANT"). THE GRANT WAS OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEE'S EMPLOYMENT.

ADC THERAPEUTICS ANNOUNCES NEW EMPLOYEE INDUCEMENT GRANT

NEW YORK, JAN. 1, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA ("ADC THERAPEUTICS" OR THE "COMPANY") (NYSE: ADCT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, DEC. 30, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA (ADC THERAPEUTICS OR THE COMPANY) (NYSE: ADCT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE "COMPANY") TODAY ANNOUNCED THE RELEASE OF ITS 2024 SUSTAINABILITY REPORT. THE REPORT HIGHLIGHTS THE COMPANY'S ENVIRONMENTAL, SOCIAL AND GOVERNANCE ("ESG") INITIATIVES AND IS ALIGNED WITH THE ISSB IFRS S1 AND S2 DISCLOSURE STANDARDS. "I'M VERY PLEASED TO RELEASE OUR FIFTH ANNUAL SUSTAINABILITY REPORT," SAID JOEY AGREE, PRESIDENT AND CHIEF EXECUTIVE OFFICER. "WE CONTINUE TO MAKE CONSIDERABLE PROGRESS ON OUR ESG INITIATIV.

Agree Realty

ADC

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC